Fidelity SPDR Advertisement
Home > Boards > Canadian > Biotechs > Nuvo Research Inc. (TSX:NRI)

ST. LOUIS and MISSISSAUGA, ON, Aug. 4 /CNW/

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
AC416 Member Profile
Member Level 
Followed By 24
Posts 2,574
Boards Moderated 1
Alias Born 09/29/06
160x600 placeholder
Nuvo Research® settles litigation with Mallinckrodt Pharmaceuticals "PR Newswire (Canada)" - 9/8/2014 7:30:00 AM
Nuvo Research® settles litigation with Mallinckrodt Pharmaceuticals "PR Newswire (US)" - 9/8/2014 7:30:00 AM
Nuvo Research® to Present at Rodman & Renshaw 16th Annual Global Investment Conference "PR Newswire (Canada)" - 9/4/2014 7:30:00 AM
Nuvo Research® to Present at Rodman & Renshaw 16th Annual Global Investment Conference "PR Newswire (US)" - 9/4/2014 7:30:00 AM
Nuvo Research® Completes Enrolment in WF10™ Phase 2 Clinical Trial "PR Newswire (Canada)" - 9/3/2014 7:30:00 AM
Nuvo Research® Completes Enrolment in WF10™ Phase 2 Clinical Trial "PR Newswire (US)" - 9/3/2014 7:30:00 AM
Nuvo Research® announces 2014 second quarter results "PR Newswire (Canada)" - 7/30/2014 5:00:00 PM
Nuvo Research® announces 2014 second quarter results "PR Newswire (US)" - 7/30/2014 5:00:00 PM
IGI Laboratories, Inc. Announces Joint Stipulation "PR Newswire (US)" - 6/26/2014 8:30:00 AM
Nuvo Research to present at Bloom Burton & Co Healthcare Investor Conference "PR Newswire (Canada)" - 6/17/2014 12:30:00 PM
Nuvo Research to present at Bloom Burton & Co Healthcare Investor Conference "PR Newswire (US)" - 6/17/2014 12:30:00 PM
Nuvo Research announces director election results of its annual general meeting "PR Newswire (Canada)" - 6/11/2014 3:30:00 PM
Nuvo Research announces director election results of its annual general meeting "PR Newswire (US)" - 6/11/2014 3:30:00 PM
Nuvo Research® announces U.S. FDA approval of third-party generic of PENNSAID 1.5% "PR Newswire (Canada)" - 5/29/2014 8:00:00 AM
Nuvo Research® announces U.S. FDA approval of third-party generic of PENNSAID 1.5% "PR Newswire (US)" - 5/29/2014 8:00:00 AM
Nuvo Research® announces 2014 first quarter results "PR Newswire (Canada)" - 4/30/2014 5:00:00 PM
Nuvo Research® announces 2014 first quarter results "PR Newswire (US)" - 4/30/2014 5:00:00 PM
Nuvo Research Announces Collaboration to Develop Topical Dermatology Products "PR Newswire (Canada)" - 4/23/2014 7:30:00 AM
Nuvo Research Announces Collaboration to Develop Topical Dermatology Products "PR Newswire (US)" - 4/23/2014 7:30:00 AM
Quinsam Monthly Update for March 2014 "Marketwired Canada" - 4/8/2014 7:46:08 AM
Nuvo Research® closes $3.1 million private placement "PR Newswire (Canada)" - 4/1/2014 7:30:00 AM
Nuvo Research® closes $3.1 million private placement "PR Newswire (US)" - 4/1/2014 7:30:00 AM
Nuvo Research announces 2013 fourth quarter & year-end results "PR Newswire (Canada)" - 2/20/2014 5:00:00 PM
Nuvo Research announces 2013 fourth quarter & year-end results "PR Newswire (US)" - 2/20/2014 5:00:00 PM
Nuvo Research Announces the U.S. Commercial Launch of PENNSAID® 2% by Mallinckrodt "PR Newswire (Canada)" - 2/10/2014 8:00:00 AM
AC416 Member Level  Tuesday, 08/04/09 10:52:08 PM
Re: None
Post # of 79 
ST. LOUIS and MISSISSAUGA, ON, Aug. 4 /CNW/ - Covidien (NYSE:COV - News), a leading global provider of healthcare products, and Nuvo Research Inc. (TSX:NRI - News), a Canadian drug development company, today announced that the U.S. Food and Drug Administration (FDA) has set a new action date under the Prescription Drug User Fee Act (PDUFA) for Pennsaid (diclofenac sodium) topical solution 1.5% w/w of November 4, 2009.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist